Tumor Analysis Method Identifies High-Risk Prostate Cancer
By LabMedica International staff writers Posted on 21 Sep 2016 |
Image: A colorized scanning electron micrograph (SEM) of human prostate cancer cells (Photo courtesy of Dr. Gopal Murti).
A new way to identify which prostate cancer patients are likely to develop aggressive types of the disease, even if their tumors at first appear to be lower risk, has been created.
Prostate cancer is a biologically heterogeneous disease with variable molecular alterations underlying cancer initiation and progression. Despite recent advances in understanding prostate cancer heterogeneity, better methods for classification of prostate cancer are still needed to improve prognostic accuracy and therapeutic outcomes.
A team of scientists led by those at Cedars-Sinai Medical Center (Los Angeles, CA, USA) computationally assembled a large virtual cohort of human prostate cancer transcriptome profiles from 38 distinct cohorts and, using pathway activation signatures of known relevance to prostate cancer, developed a novel classification system consisting of three distinct subtypes (named PCS1–3). They validated this subtyping scheme in 10 independent patient cohorts and 19 laboratory models of prostate cancer, including cell lines and genetically engineered mouse models.
The team found showed that one of the three subtypes of prostate cancer they identified, which they called PCS1, was generally aggressive. In the patients they studied, this subtype showed a high likelihood of spreading and progressing to poor clinical outcomes, including fatalities. Patients experienced poor outcomes even when the tumors had been assigned low Gleason grades. The two other subtypes, PCS2 and PCS3, progressed more slowly. Currently, patients with low-grade tumors often receive no treatment and instead are closely monitored, under a strategy known as active surveillance. The new study indicates active surveillance may not be enough for some of these patients.
An additional advantage to the new subtyping is that it can be performed on tumor cells circulating in the blood. This finding has the potential to improve real-time monitoring of tumor evolution during treatment. Michael Freeman, PhD, the study’s principal investigator said, “About 60% of prostate cancer patients we treat won't progress to aggressive cancer. The problem was that we didn't have a way of knowing which patients fall into that 60%. We hope our findings help physicians provide more patients with optimal treatments, resulting in healthier outcomes.” The study was published on September 1, 2016, in the journal Cancer Research.
Related Links:
Cedars-Sinai Medical Center
Prostate cancer is a biologically heterogeneous disease with variable molecular alterations underlying cancer initiation and progression. Despite recent advances in understanding prostate cancer heterogeneity, better methods for classification of prostate cancer are still needed to improve prognostic accuracy and therapeutic outcomes.
A team of scientists led by those at Cedars-Sinai Medical Center (Los Angeles, CA, USA) computationally assembled a large virtual cohort of human prostate cancer transcriptome profiles from 38 distinct cohorts and, using pathway activation signatures of known relevance to prostate cancer, developed a novel classification system consisting of three distinct subtypes (named PCS1–3). They validated this subtyping scheme in 10 independent patient cohorts and 19 laboratory models of prostate cancer, including cell lines and genetically engineered mouse models.
The team found showed that one of the three subtypes of prostate cancer they identified, which they called PCS1, was generally aggressive. In the patients they studied, this subtype showed a high likelihood of spreading and progressing to poor clinical outcomes, including fatalities. Patients experienced poor outcomes even when the tumors had been assigned low Gleason grades. The two other subtypes, PCS2 and PCS3, progressed more slowly. Currently, patients with low-grade tumors often receive no treatment and instead are closely monitored, under a strategy known as active surveillance. The new study indicates active surveillance may not be enough for some of these patients.
An additional advantage to the new subtyping is that it can be performed on tumor cells circulating in the blood. This finding has the potential to improve real-time monitoring of tumor evolution during treatment. Michael Freeman, PhD, the study’s principal investigator said, “About 60% of prostate cancer patients we treat won't progress to aggressive cancer. The problem was that we didn't have a way of knowing which patients fall into that 60%. We hope our findings help physicians provide more patients with optimal treatments, resulting in healthier outcomes.” The study was published on September 1, 2016, in the journal Cancer Research.
Related Links:
Cedars-Sinai Medical Center
Latest Molecular Diagnostics News
- Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays